Table 4. Univariate and multivariate Cox regression analyses of OS in 36 enrolled adult Xp11.2 RCC patients.

Covariates	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age at surgery	0.970 (0.920–1.023)	0.268	0.883 (0.756–1.032)	0.118
Sex (male vs. female)	0.569 (0.173–1.873)	0.353	2.676 (0.135–52.925)	0.518
Clinical manifestation (incidental vs. symptomatic)	0.726 (0.216–2.445)	0.606	0.057 (0.001–6044.600)	0.628
Laterality (left vs. right)	0.765 (0.223–2.621)	0.670	0.776 (0.038–15.792)	0.869
Operation (radical vs. partical)	0.034 (0.001–22.757)	0.309	36.308 (0.060–21828.088)	0.271
Tumor size	1.014 ()0.871–1.182	0.855	0.781 (0.536–1.138)	0.198
T stage (T1–T2 vs. T3–T4)	7.267 (1.737–30.397)	0.007	10.423 (0.312–348.158)	0.190
N stage (N0 vs. N1)	10.621 (2.264–49.813)	0.003	2.995 (0.320–27.975)	0.336
M stage (M0 vs. M1)	17.158 (3.349–87.910)	<0.001	19.849 (1.121–351.393)	0.042
ISUP grade (1–2 vs. 3–4)	0.209 (0.051–0.858)	0.030	4.637 (0.381–56.453)	0.229
4EBP1 expression (low vs. high)	1.476 (0.386–5.647)	0.570	1.177 (0.087–15.950)	0.902
p-4EBP1 expression (low vs. high)	6.735 (1.374–33.014)	0.019	56.111 (1.600–1967.704)	0.026
p-mTOR expression (low vs. high)	1.991 (0.597–6.638)	0.263	9.548 (0.773–117.949)	0.079
p-S6K expression (low vs. high)	1.391 (0.420–4.610)	0.589	0.346 (0.024–4.971)	0.435
p-MAPK expression (low vs. high)	1.189 (0.362–3.910)	0.775	1.188 (0.148–9.542)	0.871

OS, overall survival; Xp11.2 translocation renal cell carcinoma; ISUP, International Society of Urological Pathology; 4EBP1, eukaryotic initiation factor 4E (eIF4E) binding protein 1; p-4EBP1, phosphorylated eukaryotic initiation factor 4E (eIF4E) binding protein 1; p-mTOR, phosphorylated mammalian target of rapamycin; p-S6K, phosphorylated ribosomal protein S6 kinase; p-MAPK, phosphorylated mitogen-activated protein kinase.